Literature DB >> 17949780

Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features.

Lakshmi P Kunju1, Kirk Wojno, J Stuart Wolf, Liang Cheng, Rajal B Shah.   

Abstract

Papillary renal cell carcinoma (PRCC), a morphologically and genetically distinct subtype of RCC, is morphologically separated into 2 subtypes, type 1 and 2, for prognostic purposes. Type 1 PRCC (single layer of small cells, scant pale cytoplasm) is more common and has a favorable prognosis compared with type 2 (pseudostratified high-grade nuclei, abundant eosinophilic/oncocytic cytoplasm). We report the clinicopathologic, immunohistochemical, and molecular data of 7 adult papillary tumors with morphological features distinct from type 1 or 2 PRCC. All tumors demonstrated predominant papillary architecture, lined by cells with oncocytic cytoplasm, and nonoverlapping low Fuhrman grade nuclei (1 or 2). Foamy macrophages were noted in 2 of 7 tumors. No case demonstrated necrosis or psammoma bodies. Most tumors (6/7) were small (mean size, 2.0 cm; range, 0.8-5.7 cm) and limited to the kidney. No tumor recurrence or metastasis was identified (median follow-up, 22 months). All tumors demonstrated trisomy for 7 and 17 by fluorescence in situ hybridization analysis and uniform CK 7, CD10, and alpha-methylacyl-coenzyme A racemase expression, characteristic of PRCC. These results suggest that these tumors are distinct from type 1 (owing to oncocytic cells) and type 2 (owing to low-grade nonstratified nuclei, low stage, and good outcome). Awareness of this favorable spectrum of PRCC is important to avoid its potential misinterpretation as an aggressive type 2 PRCC (owing to oncocytic cells) or rarely as an oncocytoma (owing to oncocytic cells and low-grade nuclei). Morphologic spectrum of these PRCCs emphasizes that the future prognostic model of PRCC may need to be based primarily on the nuclear characteristics, irrespective of the cytoplasmic features.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949780     DOI: 10.1016/j.humpath.2007.05.016

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

1.  Typical signs of oncocytic papillary renal cell carcinoma in everyday clinical praxis.

Authors:  T Urge; O Hes; J Ferda; Z Chudácek; V Eret; M Michal; M Brunelli; G Martignoni; M Hora
Journal:  World J Urol       Date:  2010-05-08       Impact factor: 4.226

2.  Small oncocytic papillary renal cell carcinoma in diabetic glomerulosclerosis.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2011-10-16

3.  Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma.

Authors:  Naoto Kuroda; Naoki Kanomata; Tadanori Yamaguchi; Yoshiaki Imamura; Chisato Ohe; Noriko Sakaida; Ondrej Hes; Michal Michal; Taro Shuin; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2011-06-30       Impact factor: 2.309

4.  Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features.

Authors:  Qiu-Yuan Xia; Qiu Rao; Qin Shen; Shan-Shan Shi; Li Li; Biao Liu; Jin Zhang; Yan-Fen Wang; Qun-Li Shi; Jian-Dong Wang; Heng-Hui Ma; Zhen-Feng Lu; Bo Yu; Ru-Song Zhang; Xiao-Jun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

5.  BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms.

Authors:  Laleh Ehsani; Rishie Seth; Stephanie Bacopulos; Arun Seth; Adeboye O Osunkoya
Journal:  Tumour Biol       Date:  2012-12-15

Review 6.  MRI phenotype in renal cancer: is it clinically relevant?

Authors:  Naomi Campbell; Andrew B Rosenkrantz; Ivan Pedrosa
Journal:  Top Magn Reson Imaging       Date:  2014-04

7.  Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations.

Authors:  Joshua I Warrick; Alex Tsodikov; Lakshmi P Kunju; Arul M Chinnaiyan; Ganesh S Palapattu; Todd M Morgan; Ajjai Alva; Scott Tomlins; Angela Wu; Jeffrey S Montgomery; Khaled S Hafez; J Stuart Wolf; Alon Z Weizer; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-02-20       Impact factor: 3.466

8.  New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Authors:  Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou
Journal:  Mod Pathol       Date:  2021-03-04       Impact factor: 8.209

9.  Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy.

Authors:  Lisha Wang; Sean R Williamson; Mingsheng Wang; Darrell D Davidson; Shaobo Zhang; Lee Ann Baldridge; Xiang Du; Liang Cheng
Journal:  Mol Cancer       Date:  2014-02-26       Impact factor: 27.401

10.  Oncocytic Renal Cell Carcinoma with Tubulopapillary Growth Having a Fat Component.

Authors:  Na Rae Kim; Hyun Yee Cho
Journal:  J Pathol Transl Med       Date:  2015-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.